Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Metrics to compare | XLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLOPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.6x | −4.1x | −0.5x | |
PEG Ratio | −0.01 | −0.17 | 0.00 | |
Price/Book | 3.1x | 2.1x | 2.6x | |
Price / LTM Sales | 3.6x | 9.7x | 3.2x | |
Upside (Analyst Target) | - | 60.4% | 45.7% | |
Fair Value Upside | Unlock | 23.0% | 8.6% | Unlock |